- Research,
ILIAD project: the national "integrated cancer research site" (SIRIC) certification is extended for 5 years
SIRIC certification of the ILIAD project, in which Centrale Nantes is a partner, has been extended for a further five years! This confirms the excellence of the ILIAD SIRIC as a research site integrating medical, scientific and social research in cancer.
on January 31, 2023
Imaging and Longitudinal Investigations to Ameliorate Decision-making in multiple myeloma and breast cancer (ILIAD) is a regional consortium led by Irecan - a health cooperation grouping - which brings together Nantes University Hospital, Institut de Cancérologie and Angers University Hospital. Its partners are INSERM, the Arronax cyclotron, Centrale Nantes, the universities of Nantes and Angers and Atlanpole.
Two Centrale Nantes laboratories are involved in the project: the Jean Leray Mathematical Institute and the Laboratory of Digital Sciences of Nantes (LS2N).
The ILIAD project aims to develop a new approach to get answers to the key questions about the resistance of cancer cells to treatment, and tumour heterogeneity. A better understanding of tumour development and its environment at all stages in the patient's treatment will help combat therapeutic failure for multiple myeloma and breast cancer.
For the next five years, SIRIC ILIAD's remit will be to conduct high-level multidisciplinary research, thanks to the know-how of the project's partners: universities, health establishments, associations, engineering schools, research laboratories, etc. Ultimately, the objectives are to improve patient remission and cure rates, and to raise awareness among professionals to include and adapt the professional life of cancer patients.
Two Centrale Nantes laboratories are involved in the project: the Jean Leray Mathematical Institute and the Laboratory of Digital Sciences of Nantes (LS2N).
The ILIAD project aims to develop a new approach to get answers to the key questions about the resistance of cancer cells to treatment, and tumour heterogeneity. A better understanding of tumour development and its environment at all stages in the patient's treatment will help combat therapeutic failure for multiple myeloma and breast cancer.
For the next five years, SIRIC ILIAD's remit will be to conduct high-level multidisciplinary research, thanks to the know-how of the project's partners: universities, health establishments, associations, engineering schools, research laboratories, etc. Ultimately, the objectives are to improve patient remission and cure rates, and to raise awareness among professionals to include and adapt the professional life of cancer patients.
